ES2196016T3 - Proteina p140 y dna que codifica para la indicada proteina. - Google Patents
Proteina p140 y dna que codifica para la indicada proteina.Info
- Publication number
- ES2196016T3 ES2196016T3 ES94118524T ES94118524T ES2196016T3 ES 2196016 T3 ES2196016 T3 ES 2196016T3 ES 94118524 T ES94118524 T ES 94118524T ES 94118524 T ES94118524 T ES 94118524T ES 2196016 T3 ES2196016 T3 ES 2196016T3
- Authority
- ES
- Spain
- Prior art keywords
- protein
- prevention
- treatment
- phosphorilation
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 abstract 7
- 238000000034 method Methods 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000003345 hyperglycaemic effect Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008054 signal transmission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31580693 | 1993-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2196016T3 true ES2196016T3 (es) | 2003-12-16 |
Family
ID=18069786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES94118524T Expired - Lifetime ES2196016T3 (es) | 1993-11-24 | 1994-11-24 | Proteina p140 y dna que codifica para la indicada proteina. |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US5506205A (forum.php) |
| EP (1) | EP0659883B1 (forum.php) |
| KR (1) | KR100256664B1 (forum.php) |
| CN (1) | CN1057096C (forum.php) |
| AT (1) | ATE237683T1 (forum.php) |
| CA (1) | CA2136565C (forum.php) |
| DE (1) | DE69432511T2 (forum.php) |
| DK (1) | DK0659883T3 (forum.php) |
| ES (1) | ES2196016T3 (forum.php) |
| PT (1) | PT659883E (forum.php) |
| TW (1) | TW311913B (forum.php) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506205A (en) * | 1993-11-24 | 1996-04-09 | Ono Pharmaceutical Co., Ltd. | Polypeptide of protein p140 and DNAs encoding it |
| WO2002064093A2 (en) | 2001-02-15 | 2002-08-22 | King Pharmaceuticals, Inc. | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| GB0208089D0 (en) | 2002-04-09 | 2002-05-22 | Oxford Glycosciences Uk Ltd | Protein |
| WO2008008033A1 (en) * | 2006-07-10 | 2008-01-17 | Glucox Biotech Ab | The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia |
| US8440208B2 (en) * | 2007-05-01 | 2013-05-14 | Board Of Regents, The University Of Texas System | Chlamydial antigens as reagents for diagnosis and treatment of chlamydial infection and disease |
| US7892567B2 (en) * | 2007-10-01 | 2011-02-22 | Board Of Regents, The University Of Texas System | Methods and compositions for immunization against chlamydial infection and disease |
| JP4798125B2 (ja) * | 2007-12-13 | 2011-10-19 | 株式会社デンソー | 照度センサ |
| CN105085630A (zh) * | 2015-08-31 | 2015-11-25 | 苏州普罗达生物科技有限公司 | mTOR抑制多肽及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260200A (en) * | 1991-01-18 | 1993-11-09 | Joslin Diabetes Center, Inc. | Isolated DNA encoding an insulin receptor substrate |
| US5811396A (en) * | 1991-03-14 | 1998-09-22 | The United States Of America As Represented By The Department Of Health And Human Services | TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor |
| US5506205A (en) * | 1993-11-24 | 1996-04-09 | Ono Pharmaceutical Co., Ltd. | Polypeptide of protein p140 and DNAs encoding it |
-
1994
- 1994-11-23 US US08/348,143 patent/US5506205A/en not_active Expired - Fee Related
- 1994-11-24 ES ES94118524T patent/ES2196016T3/es not_active Expired - Lifetime
- 1994-11-24 EP EP94118524A patent/EP0659883B1/en not_active Expired - Lifetime
- 1994-11-24 CN CN94119935A patent/CN1057096C/zh not_active Expired - Fee Related
- 1994-11-24 DK DK94118524T patent/DK0659883T3/da active
- 1994-11-24 PT PT94118524T patent/PT659883E/pt unknown
- 1994-11-24 DE DE69432511T patent/DE69432511T2/de not_active Expired - Fee Related
- 1994-11-24 KR KR1019940031010A patent/KR100256664B1/ko not_active Expired - Fee Related
- 1994-11-24 CA CA002136565A patent/CA2136565C/en not_active Expired - Fee Related
- 1994-11-24 AT AT94118524T patent/ATE237683T1/de not_active IP Right Cessation
- 1994-12-13 TW TW083111593A patent/TW311913B/zh active
-
1995
- 1995-12-13 US US08/571,785 patent/US5804411A/en not_active Expired - Fee Related
-
1998
- 1998-01-08 US US09/192,435 patent/US6303320B1/en not_active Expired - Fee Related
-
2000
- 2000-04-26 US US09/558,340 patent/US6432913B1/en not_active Expired - Fee Related
-
2002
- 2002-07-03 US US10/187,958 patent/US20030170865A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP0659883B1 (en) | 2003-04-16 |
| EP0659883A3 (en) | 1997-06-25 |
| DK0659883T3 (da) | 2003-08-04 |
| US6303320B1 (en) | 2001-10-16 |
| US20030170865A1 (en) | 2003-09-11 |
| EP0659883A2 (en) | 1995-06-28 |
| CN1112127A (zh) | 1995-11-22 |
| DE69432511D1 (de) | 2003-05-22 |
| CA2136565C (en) | 1999-11-09 |
| CA2136565A1 (en) | 1995-05-25 |
| KR950014135A (ko) | 1995-06-15 |
| CN1057096C (zh) | 2000-10-04 |
| TW311913B (forum.php) | 1997-08-01 |
| KR100256664B1 (ko) | 2000-05-15 |
| DE69432511T2 (de) | 2004-04-29 |
| ATE237683T1 (de) | 2003-05-15 |
| PT659883E (pt) | 2003-07-31 |
| US6432913B1 (en) | 2002-08-13 |
| US5804411A (en) | 1998-09-08 |
| US5506205A (en) | 1996-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Turner et al. | COVID-19 vaccine-associated anaphylaxis: a statement of the World Allergy Organization Anaphylaxis Committee | |
| De Breij et al. | The antimicrobial peptide SAAP-148 combats drug-resistant bacteria and biofilms | |
| Malm et al. | Development and stability of a heat‐stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle‐income countries | |
| Arai et al. | Preparation of selenoinsulin as a long‐lasting insulin analogue | |
| Sweet et al. | Intrawound application of vancomycin for prophylaxis in instrumented thoracolumbar fusions: efficacy, drug levels, and patient outcomes | |
| Leong et al. | Cross neutralization of Afro-Asian cobra and Asian krait venoms by a Thai polyvalent snake antivenom (Neuro Polyvalent Snake Antivenom) | |
| Park et al. | Substance P promotes diabetic wound healing by modulating inflammation and restoring cellular activity of mesenchymal stem cells | |
| CN100360184C (zh) | 稳定等渗的冻干蛋白质制剂 | |
| Ettingshausen et al. | Role of von Willebrand factor in immune tolerance induction | |
| le Cotonnec et al. | Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics | |
| ES2196016T3 (es) | Proteina p140 y dna que codifica para la indicada proteina. | |
| Alonso et al. | Effects of topical Arnica gel on post‐laser treatment bruises | |
| KR970706842A (ko) | 아실화된 인슐린 동족체(Acylated Insulin Analogs) | |
| CN101172100A (zh) | 稳定等渗的冻干蛋白质制剂 | |
| Nahai et al. | IncobotulinumtoxinA (Xeomin) Background, Mechanism of Action, and Manufacturing | |
| Guptill et al. | Safety, tolerability, and pharmacokinetics of NTM-1632, a novel mixture of three monoclonal antibodies against botulinum toxin B | |
| Hawking et al. | The trypanocidal action of human serum and of baboon plasma | |
| KR890700606A (ko) | 생물학적 활성분자 | |
| Iozzo et al. | Senile lower lid entropion successfully treated with botulinum toxin A | |
| Eng et al. | Formulation development and primary degradation pathways for recombinant human nerve growth factor | |
| White et al. | Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells | |
| Lugaresi et al. | Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study | |
| Keating | Human C1-esterase inhibitor concentrate (Berinert®) | |
| Penggabean et al. | Efficacy of albendazole in the treatment of Trichuris trichuria and Giardia intestinalis infection in rural Malay communities. | |
| Hekman et al. | Isolation and identification of cyclic imide and deamidation products in heat stressed pramlintide injection drug product |